39.78
-2.24(-5.33%)
Currency In USD
| Previous Close | 42.02 |
| Open | 41.72 |
| Day High | 42.96 |
| Day Low | 36.65 |
| 52-Week High | 544 |
| 52-Week Low | 6.76 |
| Volume | 1.55M |
| Average Volume | 1.52M |
| Market Cap | 291.38M |
| PE | 0.11 |
| EPS | 356.28 |
| Moving Average 50 Days | 21.89 |
| Moving Average 200 Days | 21.38 |
| Change | -2.24 |
If you invested $1000 in Tonix Pharmaceuticals Holding Corp. (TNXP) 10 years ago, it would be worth $0 as of June 01, 2025 at a share price of $39.78. Whereas If you bought $1000 worth of Tonix Pharmaceuticals Holding Corp. (TNXP) shares 5 years ago, it would be worth $0.09 as of June 01, 2025 at a share price of $39.78.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase
GlobeNewswire Inc.
May 22, 2025 11:00 AM GMT
CHATHAM, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D.,
Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction
GlobeNewswire Inc.
May 21, 2025 11:00 AM GMT
Investigator-initiated Phase 2 trial to evaluate TNX-102 SL’s potential to reduce severity of acute stress reaction (ASR) and frequency of acute stress disorder (ASD) Trial is sponsored by the University of North Carolina (UNC) and supported by a gra
Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations
GlobeNewswire Inc.
May 14, 2025 11:00 AM GMT
Mr. Hand brings more than 20 years of strategic legal and business leadership experience across multiple functions in the biopharmaceutical industry, including nearly a decade in senior executive positions at Celgene Served on Celgene’s Executive Com